Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for Beam Therapeutics in a note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst R.

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed ...

Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the ...

2月21日《自然医学》披露的特殊病例引发全球关注：一位接受CAR-T治疗的多发性骨髓瘤患者，竟在9个月后遭遇外周T细胞淋巴瘤的突袭。这场抗癌疗法引发的"细胞叛变"，揭开了现代免疫治疗最隐秘的基因暗战。

近日，陆道培医院陆佩华院长作为第一作者和通讯作者，在国际血液学权威期刊 Blood（IF = 21）在线发表了题为「Nanobody-based Naturally Selected CD7-Targeted Chimeric Antigen ...

Beam Therapeutics Inc.’s BEAM share price has surged by 13.25%, which has investors questioning if this is right time to sell.

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel ...

See a doctor who has experience with it. You’ll find dermatologists who have experience with cutaneous T-cell lymphoma at Find a Dermatologist. Click on "Filters". Select "Any condition" and choose ...

The presence of flower cells in peripheral blood was observed in six patients (13.6%), five with acute ATLL (35.7% of acute form), and one with lymphoma ATLL (25.0% of lymphoma type) (Table 2, p = ...

Newly discovered brain cells count each bite before sending the ... "Interestingly, these neurons don't just signal an immediate stop; they help the mice to slow down their eating gradually ...